By Suzanne Elvidge, Contributing Writer
Follow Me On Twitter @suzannewriter
Cell and gene therapies (CGTs), once a dream of science fiction, are now a reality of modern medicine across the developed world. Growing numbers of proven CGTs have gained marketing approval and are available to provide treatments for patients, mostly in life-threatening and rare diseases.
According to the inaugural annual report from the International Society for Cell and Gene Therapy (ISCT), the number of CGTs with marketing authorization increased by 45 percent between 2015 and September 2018. More than a third of the approved therapies are for the treatment of cancer and blood disorders, and over half are based on autologous cells.